Future Pharmacotherapies for Male Lower Urinary Tract Symptoms
| Autor: | João F. Neves Neto, Rogerio Simonetti, Claudius Füllhase, Roberto Soler |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
business.industry Male lower urinary tract Urology Bioinformatics medicine.disease Biochemistry Pathophysiology Phosphodiesterase Type 5 Inhibitors Clinical trial Pharmacotherapy Lower urinary tract symptoms medicine Etiology business Soluble guanylyl cyclase Molecular Biology |
| Zdroj: | Current Bladder Dysfunction Reports. 9:134-141 |
| ISSN: | 1931-7220 1931-7212 |
| DOI: | 10.1007/s11884-014-0231-1 |
| Popis: | Lower urinary tract symptoms (LUTS) in men are a prevalent condition with complex and multifactorial etiology. Different types of symptoms overlap among them and treatment has evolved to a more holistic and individualized approach. Advances in the understanding of LUTS pathophysiology has led to the development of new drugs and compounds to treat male LUTS. Recently, new drugs, such as phosphodiesterase type 5 inhibitors and beta3 adrenergic agonists, have been approved for the treatment of LUTS and have just made it to clinical practice. New agents for intraprostatic injection, for instance PRX302 and NX-1207, are currently under evaluation in clinical trials with promising results. Rho-kinase inhibitors, transient receptor potential channel blockers and activators of soluble guanylyl cyclase are examples of compounds targeting different pathways involved in the pathophysiology of male LUTS, which have been tested in experimental studies. New advances in pharmacotherapy may also allow combination of drugs to achieve synergistic effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink